Fast-growing Sun Pharma eyes $5B deal for Sweden’s Meda

Carly Helfand For years, foreign companies have been buying up companies in India to gain access to the emerging market. But India's Sun Pharmaceutical Industries is looking to ...

Will Hepatitis C Become The Next Battleground Over Compulsory Licenses?

esilverman Will the new crop of hepatitis C treatments form the next battleground between the pharmaceutical industry, poor nations and patient advocates? A new report from ...

Allon Therapeutics seeks liquidation after dementia drug flops

Ryan McBride Under Canada's Bankruptcy and Insolvency Act, the Vancouver-based biotech company plans to sell off its assets to Paladin Labs. FierceBiotech News

Lung-cancer immunotherapy gets its close-up at oncology meeting

Tracy Staton The industry is abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers FiercePharma News

Up And Down The Ladder… Job Changes

esilverman Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s ...

Lung cancer spotlighted as prime target for new immunotherapies

Ryan McBride Even before the ASCO meeting opened today, the industry has been abuzz about the breakthrough potential of new immunotherapies to restore immune attacks on cancers. FierceBiotech ...

Feud at FDA as staffer’s safety review bucks agency line

Tracy Staton Outspoken FDA scientist Thomas Marciniak is stirring the pot again. This time, his target is angiotensin receptor blockers, or ARBs, taken by millions of people for high ...

Rebellious FDA Reviewer Insists ARB Heart Drugs Have Cancer Risk

esilverman Yet another instance of an FDA medical reviewer clashing with agency supervisors is playing out over a group of drugs called angiotension receptor blockers, which ...

FDA snubs Endo’s testosterone drug over REMS concerns

Ryan McBride Endo Health Solutions has lost its latest bid to gain FDA approval of a long-acting testosterone injection called Aveed, which Reuters notes has failed to gain a market ...

Serbia’s Galenika remains a wallflower with only Valeant in pursuit

Carly Helfand There's no shame in a company extending a bidding deadline in hopes of attaining a better offer. But after extending its deadline for the fourth time Thursday to June ...

Merck, Chinese R&D Firm in BRAF Inhibitor Deal

barbara.lempert Merck Enters Into Global Co-Development and Commercialization Agreement With Chinese R&D Company BeiGene on Second-Generation BRAF Inhibitor Collaboration ...

Epizyme scores latest biotech IPO victory to advance cancer pipeline

Ryan McBride The Cambridge, MA-based developer of targeted cancer drugs sold about 5.9 million shares for $ 15 per share, hitting the high end of its proposed $ 13-$ 15 per share ...
Page 2 of 3412345...102030...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS